| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2408520 | Vaccine | 2007 | 8 Pages |
Abstract
To evaluate hepatitis B virus (HBV) risk group vaccination in Amsterdam, which started in 1998, we examined 342 reported acute HBV-cases and sequenced 85 DNA isolates. The reported number of cases declined from 214 in 1992–1997 to 128 in 1998–2003, due to a decline in injecting drug users (IDU) and their heterosexual partners. Phylogenetic analyses showed that after 1998, the IDU cluster nearly disappeared, probably due to a decline in injecting. Acute HBV remained stable among men having sex with men; given their increased sexual risk behavior, vaccination has probably prevented an increase in their acute infections. Currently, 48–72% of the people who should be included in the program are still susceptible to HBV.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Robin van Houdt, Gerard J.B. Sonder, Nicole H.T.M. Dukers, Lian P.M.J. Bovee, Anneke van den Hoek, Roel A. Coutinho, Sylvia M. Bruisten,